VivoSeq
Other

Antibody-Mediated Rejection

1

Pipeline Programs↗

6

Active Trials↗

4

Companies Involved↗

Antibody-mediated Rejection is an early-stage landscape with 1 program across 4 companies. The most active players are Biogen, Sanofi, Takeda. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

40/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Biogen logo

Biogen

1 program

Phase 3Sanofi logo

Sanofi

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalArgenx logo

Argenx

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Felzartamab

Biogen

Approved
No programs

Analysis

Trial Status

11

clinical trials

Terminated2 · 18%
Recruiting2 · 18%
Completed2 · 18%
Active, not recruiting2 · 18%
Not yet recruiting1 · 9%
Withdrawn1 · 9%
Other1 · 9%

Clinical Trials

Trial Activity

11 trials

Daratumumab for Late Antibody-Mediated Rejection
Recruiting·UUniversity Hospital, Martin·N/A·NCT07081126·20 enrolled
Use of Extracorporeal Photopheresis in Kidney Transplantation: Effects on Antibody-Mediated Rejection
Recruiting·CCentre Hospitalier Universitaire de Besancon·N/A·NCT07663669·31 enrolled
BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
Active, not recruiting·Sanofi logoSanofi·Phase 2·NCT05156710·48 enrolled
A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection
Active, not recruiting·Argenx logoArgenx·Phase 2·NCT06503731·33 enrolled
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
Not yet recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06918990·25 enrolled
An Open-Label Long-Term Extension Study of Felzartamab in Participants With Antibody-Mediated Rejection or Microvascular Inflammation Previously Enrolled in TRANSCEND or TRANSPIRE
Enrolling by invitation·Biogen logoBiogen·Phase 3·NCT07444489·201 enrolled
Felzartamab in Late Antibody-Mediated Rejection
Completed·—·Phase 2·NCT05021484·22 enrolled
A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection
Completed·Takeda logoTakeda·Phase 2·NCT01147302·18 enrolled
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
Terminated·IImperial College London·Phase 3·NCT03994783·3 enrolled
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
Terminated·—·Phase 2·NCT01895127·11 enrolled
Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation
Withdrawn·PPharming Technologies B.V.·Phase 2·NCT01035593

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)